I-MAB Biopharma (NASDAQ:IMAB) Q2 2024 Earnings Conference Call August 28, 2024 8:00 AM ET

Company Participants

Sean Fu - Chief Executive Officer (interim)
Phillip Dennis - Chief Medical Officer
Joseph Skelton - Chief Financial Officer
Tyler Ehler - Vice President, Investor Relations

Conference Call Participants

Joe Catanzaro - Piper Sandler
Unknown Analyst - Jefferies
Andres Maldonado - HC Wainwright

Operator

Greetings. Welcome to I-MAB Biopharma’s first half 2024 financial results and corporate update conference call.

At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If you would like to ask a question, please press star, one on your telephone keypad and a confirmation tone will indicate your line is in the question queue. You may press star, two if you’d like to withdraw your question from the queue. For participants that are using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.

Also, if anyone should require Operator assistance during the conference, please press star, zero from your telephone keypad.

Please note that this conference is being recorded.

I’ll now hand the call over to Tyler Ehler, Vice President of Investor Relations. Tyler, you may now begin your presentation.

Tyler Ehler

Thank you Operator, and welcome everyone to I-MAB Biopharma’s first half 2024 financial results and corporate update conference call.

This morning, I-MAB issued a press release reporting its first half 2024 financial results and corporate update. To access a copy of the press release, please visit the Investor Relations page of the company’s website.

Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, which involves risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, I-MAB undertakes no obligation to update these forward-looking statements to reflect future information, events or circumstances.

This presentation includes statistical and other industry and market data that we obtain from industry publications and research surveys and studies conducted by third parties, as well as our own estimates of potential market opportunities. All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information.